Scarica l'app Stockscreener
49.46
1.02%
-0.51
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CYTK Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$49.97
Aprire:
$49.68
Volume 24 ore:
1.06M
Relative Volume:
0.93
Capitalizzazione di mercato:
$5.84B
Reddito:
$3.22M
Utile/perdita netta:
$-576.40M
Rapporto P/E:
-9.1933
EPS:
-5.38
Flusso di cassa netto:
$-407.05M
1 W Prestazione:
-2.54%
1M Prestazione:
+5.14%
6M Prestazione:
-16.18%
1 anno Prestazione:
-36.70%
Intervallo 1D:
$48.27
$50.49
Intervallo di 1 settimana:
$48.07
$52.80
Portata 52W:
$44.49
$84.05
Cytokinetics Inc Stock (CYTK) Company Profile
Nome
Cytokinetics Inc
Settore
Industria
Telefono
(650) 624-3000
Indirizzo
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Confronta CYTK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
49.46 | 5.84B | 3.22M | -576.40M | -407.05M | -5.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-22 | Iniziato | Stifel | Buy |
| 2024-11-08 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-08-13 | Downgrade | Goldman | Buy → Neutral |
| 2024-01-24 | Downgrade | UBS | Buy → Neutral |
| 2024-01-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | Iniziato | Goldman | Buy |
| 2023-11-07 | Iniziato | B. Riley Securities | Buy |
| 2023-08-15 | Iniziato | SVB Securities | Outperform |
| 2023-02-17 | Iniziato | BofA Securities | Neutral |
| 2022-12-23 | Reiterato | Needham | Buy |
| 2022-12-20 | Iniziato | Truist | Buy |
| 2022-10-11 | Iniziato | UBS | Buy |
| 2022-01-28 | Iniziato | Goldman | Buy |
| 2021-12-22 | Iniziato | Oppenheimer | Outperform |
| 2021-12-10 | Iniziato | JP Morgan | Overweight |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-03-12 | Iniziato | Wolfe Research | Outperform |
| 2021-02-18 | Iniziato | Barclays | Overweight |
| 2021-01-20 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-29 | Iniziato | Goldman | Neutral |
| 2020-07-10 | Iniziato | Raymond James | Strong Buy |
| 2020-05-05 | Iniziato | Mizuho | Buy |
| 2020-04-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-10 | Ripresa | Morgan Stanley | Equal-Weight |
| 2017-11-22 | Reiterato | Morgan Stanley | Overweight |
| 2017-11-22 | Downgrade | Needham | Strong Buy → Buy |
| 2017-11-21 | Reiterato | H.C. Wainwright | Buy |
| 2017-07-31 | Iniziato | Morgan Stanley | Overweight |
| 2017-03-08 | Iniziato | Rodman & Renshaw | Buy |
| 2017-02-06 | Aggiornamento | Needham | Buy → Strong Buy |
| 2016-12-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2016-07-28 | Reiterato | Needham | Buy |
| 2015-11-10 | Reiterato | FBR Capital | Outperform |
| 2015-11-09 | Reiterato | ROTH Capital | Buy |
| 2015-07-24 | Reiterato | MLV & Co | Buy |
| 2014-12-31 | Reiterato | ROTH Capital | Buy |
| 2014-11-04 | Aggiornamento | MLV & Co | Hold → Buy |
| 2014-04-28 | Reiterato | Needham | Buy |
Mostra tutto
Cytokinetics Inc Borsa (CYTK) Ultime notizie
Kuehn Law Encourages Investors of Cytokinetics, Inc. to Contact Law Firm - The Malaysian Reserve
Kuehn Law Encourages Investors of Cytokinetics, Inc. to Contact Law Firm -January 30, 2025 at 12:23 pm EST - Marketscreener.com
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics - Yahoo Finance
Cytokinetics awards $100K to heart disease advocacy groups - Investing.com
Cytokinetics Announces Recipients of Its Seventh Annual Communications Grant Program - GlobeNewswire
5 Patient Groups Share $100K Prize as Cytokinetics Backs Critical Heart Disease Programs - StockTitan
Nisa Investment Advisors LLC Sells 370 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - Defense World
What Are Analysts Talking About Cytokinetics (CYTK)? - Insider Monkey
Cytokinetics, Incorporated (NASDAQ:CYTK) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study - Yahoo Finance
Cantor Fitzgerald Predicts Cytokinetics FY2025 Earnings - Defense World
Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Sells $91,840.00 in Stock - MarketBeat
Cytokinetics started at buy by Stifel, aficamten highlighted - MSN
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst - Benzinga
Cytokinetics (NASDAQ:CYTK) Now Covered by Stifel Nicolaus - MarketBeat
Cantor Fitzgerald Weighs in on Cytokinetics FY2025 Earnings - MarketBeat
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Stifel starts Cytokinetics stock with Buy, $80 target By Investing.com - Investing.com Canada
Stifel starts Cytokinetics stock with Buy, $80 target - MSN
Insider Sell Alert: Fady Malik Sells 2,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus.com
Cytokinetics (NASDAQ:CYTK) Earns Buy Rating from HC Wainwright - MarketBeat
Cytokinetics Announces Start of AMBER-HFpEF, a Phase 2 - GlobeNewswire
Cytokinetics Announces Start of AMBER-HFpEF, a Phase 2 Clinical Trial of CK-586 in Patients With Symptomatic Heart Failure With Preserved Ejection Fraction - Yahoo Finance
Cytokinetics' SWOT analysis: aficamten's potential drives stock outlook By Investing.com - Investing.com Canada
Cytokinetics' SWOT analysis: aficamten's potential drives stock outlook - Investing.com
Cytokinetics (NASDAQ:CYTK) Given "Market Outperform" Rating at JMP Securities - MarketBeat
S&P 500 Futures Rise in Premarket Trading; Trump Media & Tech, Cytokinetics Lag - Barron's
Cytokinetics Announces 2025 Corporate Milestones and Vision 2030 - GlobeNewswire
Cytokinetics Sets FDA Review Date for Aficamten, Unveils Ambitious 2030 Global Expansion Plan - StockTitan
HC Wainwright Reiterates “Buy” Rating for Cytokinetics (NASDAQ:CYTK) - Defense World
Cytokinetics EVP sells shares worth $98,640 By Investing.com - Investing.com South Africa
Cytokinetics EVP sells shares worth $98,640 - Investing.com India
Cytokinetics (NASDAQ:CYTK) Sets New 1-Year LowTime to Sell? - MarketBeat
Insider Selling: Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Sells 2,000 Shares of Stock - MarketBeat
Cytokinetics (NASDAQ:CYTK) Receives Buy Rating from HC Wainwright - MarketBeat
Vanguard Group Inc's Strategic Acquisition of Cytokinetics Inc S - GuruFocus.com
Cytokinetics’ SWOT analysis: aficamten progress boosts stock outlook By Investing.com - Investing.com Nigeria
Cytokinetics' SWOT analysis: aficamten progress boosts stock outlook - Investing.com
Cytokinetics' SWOT analysis: aficamten progress boosts stock outlook By Investing.com - Investing.com Canada
Congestive Heart Failure Market Expected to rise, 2034 | Novartis, Boehringer Ingelheim, Eli Lilly, Bayer, Merck, AstraZeneca, Amgen, Otsuka Pharmaceutical, Cytokinetics, Mesoblast, Novo Nordisk - Barchart
Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Cytokinetics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
10 Clinical Trials Of 2024 – Hits, Misses And Some In Between - News & Insights
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Cytokinetics Awards Stock Grants to New Employees, Including Options and Performance Units - StockTitan
Cytokinetics Inc Azioni (CYTK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cytokinetics Inc Azioni (CYTK) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Malik Fady Ibraham | EVP Research & Development |
Jan 21 '25 |
Sale |
45.92 |
2,000 |
91,840 |
116,071 |
| Malik Fady Ibraham | EVP Research & Development |
Jan 07 '25 |
Option Exercise |
10.60 |
2,000 |
21,200 |
118,071 |
| Malik Fady Ibraham | EVP Research & Development |
Jan 07 '25 |
Sale |
49.32 |
2,000 |
98,640 |
116,071 |
3.95%
2.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):